Immunovant Inc
NASDAQ:IMVT
Immunovant Inc
NASDAQ:IMVT
Price:
28.42 USD
-1.83%
Market Closed
Updated:
May 29, 2024
Immunovant Inc
Additional Paid In Capital
|
Immunovant Inc
Additional Paid In Capital Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Additional Paid In Capital Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Additional Paid In Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Immunovant Inc
NASDAQ:IMVT
|
Additional Paid In Capital
$928m
|
CAGR 3-Years
71%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Additional Paid In Capital
$20.7B
|
CAGR 3-Years
5%
|
CAGR 5-Years
7%
|
CAGR 10-Years
18%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Additional Paid In Capital
$6.8B
|
CAGR 3-Years
19%
|
CAGR 5-Years
22%
|
CAGR 10-Years
2%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Additional Paid In Capital
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Additional Paid In Capital
$7.3B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
3%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Additional Paid In Capital
$11.9B
|
CAGR 3-Years
20%
|
CAGR 5-Years
23%
|
CAGR 10-Years
18%
|
See Also
What is Immunovant Inc's Additional Paid In Capital?
Additional Paid In Capital
928m
USD
928m
USD
Based on the financial report for Mar 31, 2023, Immunovant Inc's Additional Paid In Capital amounts to 928m USD.
What is Immunovant Inc's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 3Y
71%
71%
Over the last year, the Additional Paid In Capital growth was 13%. The average annual Additional Paid In Capital growth rates for Immunovant Inc have been 71% over the past three years .
You don't have any saved screeners yet
